DGIdb - LINSITINIB Drug Record

LINSITINIB chembl:CHEMBL1091644 Antineoplastic

Alternate Names:

ASP-7487
OSI-906AA
LINSITINIB
OSI-906

Drug Info:

Pharmaceutical Developer	OSI Pharmaceuticals
Source Reported Drug Name(s)	OSI-906
Drug Class	IGF1R Inhibitor
FDA Approval	not approved
Drug Class	small molecule
Drug Indications	antineoplastic agent
Drug Class	Kinase Inhibitors

(6 More Sources)

Publications:

de Lint et al., 2016, Sensitizing Triple-Negative Breast Cancer to PI3K Inhibition by Cotargeting IGF1R., Mol. Cancer Ther.
Ma et al., 2016, InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma., Clin. Cancer Res.
Vidal et al., 2015, A targetable GATA2-IGF2 axis confers aggressiveness in lethal prostate cancer., Cancer Cell
Hayes et al., 2016, Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression., Cancer Cell

LINSITINIB IGF1R

Interaction Score: 1.67

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name OSI-906

Novel drug target Established target

Notes

PMIDs:
None found

Sources:
TALC MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial ChemblInteractions CancerCommons TTD
LINSITINIB IGF2

Interaction Score: 1.26

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25670080

Sources:
CIViC
LINSITINIB INSR

Interaction Score: 0.29

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Insulin receptor inhibitor

Direct Interaction yes

Notes

PMIDs:
None found

Sources:
TALC ChemblInteractions
LINSITINIB PTEN

Interaction Score: 0.18

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Gefitinib + Linsitinib

Indication/Tumor Type glioblastoma multiforme

Response Type sensitive

PMIDs:
26561558

Sources:
JAX-CKB
LINSITINIB KRAS

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Linsitinib + SCH772984

Indication/Tumor Type pancreatic ductal adenocarcinoma

Response Type sensitive

PMIDs:
26725216

Sources:
JAX-CKB
LINSITINIB PIK3CA

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy GDC-0941 + Linsitinib

Indication/Tumor Type triple-receptor negative breast cancer

Response Type sensitive

PMIDs:
27196766

Sources:
JAX-CKB
LINSITINIB EGFR

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Gefitinib + Linsitinib

Indication/Tumor Type glioblastoma multiforme

Response Type sensitive

PMIDs:
26561558

Sources:
JAX-CKB

MyCancerGenome: LINSITINIB
- Version: 20-Jun-2017
Alternate Names:

OSI-906 Development Name

LINSITINIB Generic Name

Drug Info:

Drug Class Kinase Inhibitors

Publications:
CancerCommons: LINSITINIB
- Version: 25-July-2013
Alternate Names:

3-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol PubChem Drug Name

11640390 PubChem Drug ID

OSI-906 Drug Trade Name

Drug Info:

Drug Class IGF1R Inhibitor

Source Reported Drug Name(s) OSI-906

Pharmaceutical Developer OSI Pharmaceuticals

Publications:
TdgClinicalTrial: OSI-906
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antineoplastic agent

Drug Class small molecule

FDA Approval not approved

Publications:

JAX-CKB: Linsitinib

Version: 27-September-2017

Alternate Names:

Drug Info:

Publications:

de Lint et al., 2016, Sensitizing Triple-Negative Breast Cancer to PI3K Inhibition by Cotargeting IGF1R., Mol. Cancer Ther.

Hayes et al., 2016, Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression., Cancer Cell

Ma et al., 2016, InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma., Clin. Cancer Res.

CIViC: LINSITINIB
- Version: 14-September-2020
Alternate Names:

Drug Info:

Publications:

Vidal et al., 2015, A targetable GATA2-IGF2 axis confers aggressiveness in lethal prostate cancer., Cancer Cell
TTD: OSI-906
- Version: 2020.06.01
Alternate Names:

D01GFX TTD Drug ID

Drug Info:

Publications:
TALC: LINSITINIB
- Version: 12-May-2016
Alternate Names:

LINSITINIB Primary Drug Name

LINSITINIB Drug Generic Name

OSI-906 Drug Synonym

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL1091644
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL1091644
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:
ClearityFoundationClinicalTrial: LINSITINIB
- Version: 15-June-2013
Alternate Names:

Drug Info:

Publications:

Mechanism of Interaction	Insulin receptor inhibitor
Direct Interaction	yes
Notes

combination therapy	Gefitinib + Linsitinib
Indication/Tumor Type	glioblastoma multiforme
Response Type	sensitive

combination therapy	Linsitinib + SCH772984
Indication/Tumor Type	pancreatic ductal adenocarcinoma
Response Type	sensitive

combination therapy	GDC-0941 + Linsitinib
Indication/Tumor Type	triple-receptor negative breast cancer
Response Type	sensitive

3-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol	PubChem Drug Name
11640390	PubChem Drug ID
OSI-906	Drug Trade Name

LINSITINIB	Primary Drug Name
LINSITINIB	Drug Generic Name
OSI-906	Drug Synonym

Trial Name	OSI-906
Novel drug target	Established target
Notes

LINSITINIB Drug Record

LINSITINIB chembl:CHEMBL1091644 Antineoplastic

Alternate Names:

Drug Info:

Publications:

LINSITINIB IGF1R

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name OSI-906 Novel drug target Established target Notes

PMIDs: None found

Sources: TALC MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial ChemblInteractions CancerCommons TTD

LINSITINIB IGF2

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 25670080

Sources: CIViC

LINSITINIB INSR

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Insulin receptor inhibitor Direct Interaction yes Notes

PMIDs: None found

Sources: TALC ChemblInteractions

LINSITINIB PTEN

Interaction Types & Directionality: n/a

Interaction Info: combination therapy Gefitinib + Linsitinib Indication/Tumor Type glioblastoma multiforme Response Type sensitive

PMIDs: 26561558

Sources: JAX-CKB

LINSITINIB KRAS

Interaction Types & Directionality: n/a

Interaction Info: combination therapy Linsitinib + SCH772984 Indication/Tumor Type pancreatic ductal adenocarcinoma Response Type sensitive

PMIDs: 26725216

Sources: JAX-CKB

LINSITINIB PIK3CA

Interaction Types & Directionality: n/a

Interaction Info: combination therapy GDC-0941 + Linsitinib Indication/Tumor Type triple-receptor negative breast cancer Response Type sensitive

PMIDs: 27196766

Sources: JAX-CKB

LINSITINIB EGFR

Interaction Types & Directionality: n/a

Interaction Info: combination therapy Gefitinib + Linsitinib Indication/Tumor Type glioblastoma multiforme Response Type sensitive

PMIDs: 26561558

Sources: JAX-CKB

MyCancerGenome: LINSITINIB

Alternate Names: OSI-906 Development Name LINSITINIB Generic Name

Drug Info: Drug Class Kinase Inhibitors

Publications:

CancerCommons: LINSITINIB

Alternate Names: 3-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol PubChem Drug Name 11640390 PubChem Drug ID OSI-906 Drug Trade Name

Drug Info: Drug Class IGF1R Inhibitor Source Reported Drug Name(s) OSI-906 Pharmaceutical Developer OSI Pharmaceuticals

Publications:

TdgClinicalTrial: OSI-906

Alternate Names:

Drug Info: Drug Indications antineoplastic agent Drug Class small molecule FDA Approval not approved

Publications:

JAX-CKB: Linsitinib

Alternate Names:

Drug Info:

CIViC: LINSITINIB

Alternate Names:

Drug Info:

Publications: Vidal et al., 2015, A targetable GATA2-IGF2 axis confers aggressiveness in lethal prostate cancer., Cancer Cell

TTD: OSI-906

Alternate Names: D01GFX TTD Drug ID

Drug Info:

Publications:

TALC: LINSITINIB

Alternate Names: LINSITINIB Primary Drug Name LINSITINIB Drug Generic Name OSI-906 Drug Synonym

Drug Info:

Publications:

ChemblDrugs: chembl:CHEMBL1091644

Alternate Names:

Drug Info:

Publications:

ChemblInteractions: CHEMBL1091644

Alternate Names:

Drug Info:

Publications:

ClearityFoundationClinicalTrial: LINSITINIB

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name OSI-906

Novel drug target Established target

Notes

PMIDs:
None found

Sources:
TALC MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial ChemblInteractions CancerCommons TTD

Interaction Types & Directionality:

n/a

PMIDs:
25670080

Sources:
CIViC

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Insulin receptor inhibitor

Direct Interaction yes

Notes

PMIDs:
None found

Sources:
TALC ChemblInteractions

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Gefitinib + Linsitinib

Indication/Tumor Type glioblastoma multiforme

Response Type sensitive

PMIDs:
26561558

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Linsitinib + SCH772984

Indication/Tumor Type pancreatic ductal adenocarcinoma

Response Type sensitive

PMIDs:
26725216

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy GDC-0941 + Linsitinib

Indication/Tumor Type triple-receptor negative breast cancer

Response Type sensitive

PMIDs:
27196766

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Gefitinib + Linsitinib

Indication/Tumor Type glioblastoma multiforme

Response Type sensitive

PMIDs:
26561558

Sources:
JAX-CKB

Alternate Names:

OSI-906 Development Name

LINSITINIB Generic Name

Drug Info:

Drug Class Kinase Inhibitors

Alternate Names:

3-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol PubChem Drug Name

11640390 PubChem Drug ID

OSI-906 Drug Trade Name

Drug Info:

Drug Class IGF1R Inhibitor

Source Reported Drug Name(s) OSI-906

Pharmaceutical Developer OSI Pharmaceuticals

Drug Info:

Drug Indications antineoplastic agent

Drug Class small molecule

FDA Approval not approved

Publications:

Vidal et al., 2015, A targetable GATA2-IGF2 axis confers aggressiveness in lethal prostate cancer., Cancer Cell

Alternate Names:

D01GFX TTD Drug ID

Alternate Names:

LINSITINIB Primary Drug Name

LINSITINIB Drug Generic Name

OSI-906 Drug Synonym